Literature DB >> 15223156

Multiple sclerosis: management issues during pregnancy.

Simone Ferrero1, Stefano Pretta, Nicola Ragni.   

Abstract

Care of pregnant women with multiple sclerosis (MS) is challenging because of the multiple physiological changes associated with pregnancy and the need to consider the impact of any intervention on the foetus. Pregnancy is associated with clinical MS stability or improvement, while the rate of relapse rises significantly during the first three months post-partum before coming back to its level prior to pregnancy. Gestational history has no influence on long-term disability and MS does not seem to influence pregnancy or the child's health. Apart from methotrexate and cyclophosphamide, most drugs used regularly to treat MS can safely be used by pregnant women. Intravenous steroids may be used with relative safety during pregnancy. Maternal use of azathioprine is not associated with an increased risk of congenital malformations, though impaired foetal immunity, intrauterine growth retardation and prematurity are occasionally observed. Cyclosporin is not teratogenic, but may be associated with growth retardation and prematurity. Pregnancy should be avoided in women treated with methotrexate because of its known abortifacient effects and risk of causing typical malformations. Cyclophosphamide is teratogenic in animals, but population studies have not conclusively demonstrated its teratogenicity in humans. Until information is available regarding safety, glatiramer acetate, mitoxantrone, interferon-beta-1a and interferon-beta-1b should be discontinued before an anticipated pregnancy. Women with MS are no more likely to experience delivery complications than are women without MS and the mode of delivery should be decided strictly on obstetrical criteria. Spinal, epidural and general anaesthesia can all be used safely in MS patients. Young women with MS who desire children can be reassured that their infants are not at increased risk of malformations, preterm delivery, low birth weight, or infant death. The progressive nature of the disease may motivate affected women to start or complete their families as soon as possible.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15223156     DOI: 10.1016/j.ejogrb.2003.10.020

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  18 in total

1.  Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach.

Authors:  Maria Pia Amato; Antonio Bertolotto; Roberto Brunelli; Paola Cavalla; Benedetta Goretti; Maria Giovanna Marrosu; Francesco Patti; Carlo Pozzilli; Leandro Provinciali; Nicola Rizzo; Nicola Strobelt; Gioacchino Tedeschi; Maria Trojano; Giancarlo Comi
Journal:  Neurol Sci       Date:  2017-08-02       Impact factor: 3.307

2.  Increased MS relapse rate during assisted reproduction technique.

Authors:  Kerstin Hellwig; Christian Beste; Niels Brune; Aiden Haghikia; Thomas Müller; Sebastian Schimrigk; Ralf Gold
Journal:  J Neurol       Date:  2008-04-16       Impact factor: 4.849

Review 3.  Does the immune system induce labor? Lessons from preterm deliveries in women with autoimmune diseases.

Authors:  Norbert Gleicher
Journal:  Clin Rev Allergy Immunol       Date:  2010-12       Impact factor: 8.667

4.  9 Human Immunoglobulins.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

Review 5.  [Intravenous immunoglobulins in multiple sclerosis. An update].

Authors:  S Schwarz; H-M Meinck; B Storch-Hagenlocher
Journal:  Nervenarzt       Date:  2009-08       Impact factor: 1.214

6.  Male microchimerism in peripheral blood leukocytes from women with multiple sclerosis.

Authors:  Evan M Bloch; William F Reed; Tzong-Hae Lee; Leilani Montalvo; Stephen Shiboski; Brian Custer; Lisa F Barcellos
Journal:  Chimerism       Date:  2011-01

7.  Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis?

Authors:  F Patti; T Cavallaro; S Lo Fermo; A Nicoletti; V Cimino; R Vecchio; P Laisa; R Zarbo; M Zappia
Journal:  J Neurol       Date:  2008-07-28       Impact factor: 4.849

Review 8.  Multiple sclerosis and pregnancy: therapeutic considerations.

Authors:  Maria K Houtchens; Channa M Kolb
Journal:  J Neurol       Date:  2012-08-25       Impact factor: 4.849

9.  Pregnancy Outcomes in Women With Multiple Sclerosis.

Authors:  Sarah C MacDonald; Thomas F McElrath; Sonia Hernández-Díaz
Journal:  Am J Epidemiol       Date:  2019-01-01       Impact factor: 4.897

10.  Is Fertility Affected in Women of Childbearing Age with Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder?

Authors:  Niyousha Sadeghpour; Omid Mirmosayyeb; Geir Bjørklund; Vahid Shaygannejad
Journal:  J Mol Neurosci       Date:  2020-08-01       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.